Cullen M H
Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
Oncology. 1993 Apr;50 Suppl 1:31-4. doi: 10.1159/000227245.
Mitomycin, ifosfamide, and cisplatin have demonstrated the best single-agent activity thus far in patients with non-small cell lung cancer (NSCLC), the most common malignant disease in the western world. For this reason, we initiated a phase II study, giving these three agents in combination (designated MIC) to 74 patients with inoperable NSCLC. Sixty-six patients were evaluable for response, of whom 30 (45%) demonstrated a partial response and 7 (11%) a complete response. These results, along with those obtained in two other phase II trials of MIC in NSCLC, promoted us to begin a large-scale, multicenter, phase III study of MIC in patients with inoperable limited-stage NSCLC. In this ongoing study, patients have been randomized to receive treatment with MIC and radiotherapy or radiotherapy alone. We hope to resolve the issue of whether a survival advantage is conferred on NSCLC patients treated with radiotherapy in combination with this promising chemotherapeutic regimen.
丝裂霉素、异环磷酰胺和顺铂是目前在非小细胞肺癌（NSCLC）患者中显示出最佳单药活性的药物，NSCLC是西方世界最常见的恶性疾病。因此，我们开展了一项II期研究，将这三种药物联合使用（命名为MIC），用于74例无法手术的NSCLC患者。66例患者可评估疗效，其中30例（45%）显示部分缓解，7例（11%）显示完全缓解。这些结果，以及在另外两项NSCLC患者的MIC II期试验中获得的结果，促使我们开始一项针对无法手术的局限期NSCLC患者的大规模、多中心III期MIC研究。在这项正在进行的研究中，患者被随机分配接受MIC联合放疗或单纯放疗。我们希望解决在NSCLC患者中，放疗联合这种有前景的化疗方案是否能带来生存优势这一问题。
